Discover how a groundbreaking class of medications, GLP-1 agonists, are revolutionizing the treatment of sleep apnea. In this insightful discussion, Dr. Craig Walker and Terry Roberts delve into the profound impact these drugs can have on addressing the underlying causes of sleep apnea, particularly obesity.

Explore the recent approval of Trulicity for the treatment of sleep apnea, and learn about the potential for other GLP-1 agonists to be utilized in this application.

Understand the significant risks associated with untreated sleep apnea, including its strong link to atrial fibrillation, congestive heart failure, and hypertension.

Gain valuable insights into how GLP-1 agonists can not only treat the symptoms of sleep apnea but also address the root causes, potentially eliminating the need for cumbersome devices like CPAP. Discover the additional benefits these medications offer in managing diabetes and improving overall cardiovascular health.

Whether you or a loved one are struggling with sleep apnea or simply interested in the latest advancements in this field, this episode provides a comprehensive understanding of the transformative potential of GLP-1 agonists in the realm of sleep apnea and beyond.

Key Areas Covered:

• Overview of sleep apnea, including the two main types (central and obstructive)
• Risks and complications associated with untreated sleep apnea
• Traditional treatment options and their limitations
• Approval of Trulicity for the treatment of sleep apnea
• Potential of GLP-1 agonists to address the underlying causes of sleep apnea, particularly obesity
• Additional benefits of GLP-1 agonists in managing diabetes and cardiovascular health
  
  

💙 Take charge of your heart health today!
If you’re concerned about your risk, visit cardio.com to schedule a screening with Dr. Walker and his team.

📌 Don't forget to follow and share!

--- For more information, visit: ---
Facebook Page: facebook.com/profile.php?id=61558432490919
www.cardio.com